The Effect of an α-Glucosidase Inhibitor and Insulin on Glucose Metabolism and Lipid Profiles in Non-Insulin-Dependent Diabetes Mellitus

Abstract

Studies were carried out to assess various ways of improving glycaemic control and lipid profiles of patients with non-insulin-dependent diabetes mellitus (NIDDM) in whom glucose metabolism was poor. Part or all of the dose of the sulphonylurea that had been used to treat patients in Group 1 (n = 8) was replaced by an α-glucosidase inhibitor. Symptoms related to hypoglycaemia disappeared and the postprandial blood glucose level was significantly increased (P < 0.043) but serum lipid levels were not significantly altered and the mean glycosylated haemoglobin level was unchanged. In Group 2 (n = 10) patients, a large part of the insulin dose was replaced by an α-glucosidase inhibitor. Hypoglycaemia-related symptoms disappeared but there were no significant changes in lipid profiles, postprandial blood glucose or glycosylated haemoglobin levels. The third group of patients (n = 9) had been treated with insulin alone and were given additional α-glucosidase inhibitor without changing their insulin dose. This did not significantly change their lipid profiles, postprandial blood glucose or glycosylated haemoglobin levels. In Group 4 (n = 9) the addition of an α-glucosidase inhibitor to the initial sulphonylurea did not produce any significant changes in mean postprandial blood glucose or glycosylated haemoglobin levels. The results for individual patients indicated that the glycosylated haemoglobin levels had improved after the change of treatment only in those patients whose connective peptide immunoreactivity was > 6.0 ng/ml.

Keywords

α-Glucosidase inhibitor Sulphonylurea Insulin Non-insulin-dependent diabetes mellitus Glucose metabolism Lipid profile Connective peptide immunoreactivity

Get full access to this article

View all access options for this article.

References

DeFronzo

: Insulin resistance: a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–194.

Okada

Ishii

Tanokuchi

: The effect of a very low dose of tolbutamide combined with an α-glucosidase inhibitor in non-insulin-dependent diabetes mellitus. J Int Med Res 1996; 24: 438–442.

Goto

Baba

Nakagawa

: Optimal dose finding study of AO-128 treated NIDDM (1). Jpn J Clin Exp Med 1992; 69: 1211–1236.

Goto

Baba

Nakagawa

: Optimal dose finding study of AO-128 treated NIDDM (2). Jpn J Clin Exp Med 1992; 69: 1237–1256.

Baba

: α-glucosidase inhibitor. Med Pract 1993; 10: 189–194.

Okada

Ishii

Hamada

: Can α-glucosidase inhibitors reduce the dosage of sulphonylurea compounds needed by patients with non-insulin-dependent diabetes mellitus? J Int Med Res 1996; 23: 502–507.

Okada

Ishii

Hamada

: Can α-glucosidase inhibitors reduce the insulin dosage administered to patients with non-insulin-dependent diabetes mellitus? J Int Med Res 1996; 23: 487–491.

Okada

Ishii

Tanokuchi

: No effect of an α-glucosidase inhibitor on glucose metabolism in patients with non-insulin-dependent diabetes mellitus and low function of pancreatic β-cells. J Int Med Res 1995; 23: 274–298.

Okada

: Basic Diabetes Education as a Model. Osaka: Asahi Culture Center, 1994.

10.

WHO Study Group on Diabetes Mellitus: Diabetes Mellitus. Report No. 727. WHO Technical Report Series, Geneva: WHO, 1985.

11.

Okada

Ichiki

Tanokuchi

: Determination of a cut-off point between treatable and untreatable ranges of nephropathy estimated from the urinary albumin index (UAI) in NIDDM. In: Recent Trends of Diabetes Mellitus in West Asia (Mimura G and Zhiisheng C, eds). Amsterdam: Elsevier Science Publishers BV, 1990; pp 239–242.

12.

Okada

Tanokuchi

Ichiki

: Significance of urinary albumin index in the urine collected arbitrarily in the morning. Acta Med Okayama 1990; 46: 165–168.

13.

Odaka

: Effect of a disaccharidase inhibitor, AO–128, on postprandial hyperglycaemia in rats. J Jap Soc Nutr Fd Sci 1992; 45: 27–31.

14.

Okada

: Treatment of Type 1 diabetes using a pen-style delivery system and a preparation combining short- and intermediate-acting insulin. J Int Med Res 1993; 21: 216–223.

15.

Richmond

: Precipitation and properties of a cholesterol oxidase from Nocardia sp. and its preparation to the enzymatic assay of total cholesterol in serum. Clin Chem 1973; 19: 1350–1356.

16.

Fossati

Prencipe

: Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28: 2077–2080.

17.

Burstein

Scholnick

Morfin

: Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970; 11: 583–595.

18.

Okada

Ishii

Hamada

: Insulin secretion levels necessary for efficacy of an α-glucosidase inhibitor on glucose metabolism in patients with non-insulin-dependent diabetes mellitus. J Int Med Res 1996; 23: 497–501.